No­var­tis bags a new eczema drug, builds der­ma­tol­ogy pipeline with Ziar­co buy­out

Two days af­ter Pfiz­er won an FDA ap­proval for a new drug for atopic der­mati­tis which it ac­quired in a $5.2 bil­lion buy­out, No­var­tis has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.